Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.71 Average PT from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received a consensus rating of “Buy” from the five research firms that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $26.71.

Several equities analysts have recently commented on the stock. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Wednesday, March 27th. Bank of America started coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 10th.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $15.92 on Tuesday. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $17.50. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 29.48, a PEG ratio of 1.40 and a beta of 0.89. The firm’s 50 day moving average price is $15.68 and its two-hundred day moving average price is $15.00.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. The business had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million. On average, research analysts forecast that Catalyst Pharmaceuticals will post 1.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the transaction, the insider now owns 124,433 shares of the company’s stock, valued at approximately $2,045,678.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Catalyst Pharmaceuticals by 25.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 5,044 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Catalyst Pharmaceuticals by 5.3% during the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 1,456 shares during the last quarter. LSV Asset Management raised its position in shares of Catalyst Pharmaceuticals by 25.6% during the third quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock valued at $14,505,000 after buying an additional 253,100 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at about $797,000. Finally, Victory Capital Management Inc. raised its position in shares of Catalyst Pharmaceuticals by 6.0% during the third quarter. Victory Capital Management Inc. now owns 311,355 shares of the biopharmaceutical company’s stock valued at $3,640,000 after buying an additional 17,697 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.